Nikolousis, M and Robinson, S and Nagra, S and Brookes, C and Kinsella, F and Tauro, S and Jeffries, S and Griffiths, M and Mahendra, P and Cook, M and Paneesha, S and Lovell, R and Kishore, B and Chaganti, S and Malladi, R and Raghavan, M and Moss, P and Milligan, D and Craddock, C (2013) Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. Leukemia research, 37 (5). pp. 561-565. ISSN 1873-5835. This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their Athens login IDsFull text not available from this repository.
In this multicentre retrospective study we have studied the impact of T cell chimerism on the outcome of 133 patients undergoing an alemtuzumab based reduced intensity conditioning allograft (RIC). The median age of the patients was 50 years (range 42-55 years). 77 patients were transplanted using an HLA identical sibling donor while 56 patients received a fully matched volunteer unrelated donor graft. 64 patients had a lymphoid malignancy and 69 were transplanted for a myeloid malignancy. 38 patients (29%) relapsed with no significant difference in risk of relapse between patients developing full donor and mixed donor chimerism in the T-cell compartment on D+90 and D+180 post transplant. Day 90 full donor T cell chimerism correlated with an increased incidence of acute GVHD according to NIH criteria (p=0.0004) and the subsequent development of chronic GVHD. Consistent with previous observations, our results confirmed a correlation between the establishment of T cell full donor chimerism and acute GVHD in T deplete RIC allografts. However our study failed to identify any correlation between T cell chimerism and relapse risk and challenge the use of pre-emptive donor lymphocyte infusions (DLI) in patients with mixed T cell chimerism transplanted using an alemtuzumab based RIC regimen.
|Additional Information:||This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their Athens login IDs|
|Subjects:||WH Haemic and lymphatic systems. Haematology|
|Divisions:||Clinical Support > Pathology
Planned IP Care > Oncology and Clinical Haematology
|Depositing User:||Mrs Yolande Brookes|
|Date Deposited:||03 Jul 2014 13:45|
|Last Modified:||05 Jul 2014 10:35|
Actions (login required)